PL173303B1 - Sposób wytwarzania nowych związków heterocyklicznych - Google Patents

Sposób wytwarzania nowych związków heterocyklicznych

Info

Publication number
PL173303B1
PL173303B1 PL92295044A PL29504492A PL173303B1 PL 173303 B1 PL173303 B1 PL 173303B1 PL 92295044 A PL92295044 A PL 92295044A PL 29504492 A PL29504492 A PL 29504492A PL 173303 B1 PL173303 B1 PL 173303B1
Authority
PL
Poland
Prior art keywords
formula
group
compound
methyl
alkyl
Prior art date
Application number
PL92295044A
Other languages
English (en)
Polish (pl)
Other versions
PL295044A1 (en
Inventor
Takehiko Naka
Yoshiyuki Inada
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PL295044A1 publication Critical patent/PL295044A1/xx
Publication of PL173303B1 publication Critical patent/PL173303B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
PL92295044A 1991-06-27 1992-06-26 Sposób wytwarzania nowych związków heterocyklicznych PL173303B1 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP15719491 1991-06-27
JP18888291 1991-07-29
JP19205491 1991-07-31
JP28821791 1991-08-12
JP23976491 1991-09-19
JP34110791 1991-12-24

Publications (2)

Publication Number Publication Date
PL295044A1 PL295044A1 (en) 1993-03-08
PL173303B1 true PL173303B1 (pl) 1998-02-27

Family

ID=27553195

Family Applications (1)

Application Number Title Priority Date Filing Date
PL92295044A PL173303B1 (pl) 1991-06-27 1992-06-26 Sposób wytwarzania nowych związków heterocyklicznych

Country Status (19)

Country Link
US (6) US5243054A (hu)
EP (1) EP0520423B1 (hu)
JP (2) JP2645962B2 (hu)
KR (1) KR100233689B1 (hu)
AT (1) ATE240323T1 (hu)
CA (1) CA2072541C (hu)
DE (1) DE69233057T2 (hu)
DK (1) DK0520423T3 (hu)
ES (1) ES2194009T3 (hu)
FI (1) FI113653B (hu)
HU (2) HU218792B (hu)
IE (1) IE921861A1 (hu)
IL (1) IL102183A (hu)
NO (1) NO300734B1 (hu)
NZ (1) NZ243304A (hu)
PL (1) PL173303B1 (hu)
PT (1) PT520423E (hu)
SG (1) SG65550A1 (hu)
SK (1) SK281077B6 (hu)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5583229A (en) * 1992-12-07 1996-12-10 Eisai Co., Ltd. Process for the preparation of imidazopyridine derivatives
GB9217820D0 (en) * 1992-08-21 1992-10-07 Fujisawa Pharmaceutical Co New use
EP0829479B1 (en) * 1992-09-14 2004-04-14 Takeda Chemical Industries, Ltd. Heterocyclic compounds and their use as angiotensin II antagonists
ATE204276T1 (de) * 1992-12-22 2001-09-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen mit angiotensin-ii- antagonistischer wirkung und ihre anwendung
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
DE4318813A1 (de) * 1993-06-07 1994-12-08 Merck Patent Gmbh Imidazopyridine
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
AP9400651A0 (en) * 1993-07-15 1995-12-30 Pfizer Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists.
EP0736023B1 (en) * 1993-12-21 1998-07-08 Smithkline Beecham Plc Indole, indoline and quinoline derivatives with 5ht 1d (anti-depressive) activity
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
EP0862573A1 (en) * 1995-10-19 1998-09-09 Takeda Chemical Industries, Ltd. Thienopyridine derivatives as gonadotropin releasing hormone antagonists
EP0781774B1 (en) * 1995-12-08 2002-07-31 Takeda Chemical Industries, Ltd. Prolactin production inhibitory agents
US6001850A (en) * 1996-04-26 1999-12-14 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their production and use
WO1999001454A1 (en) * 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AU8996698A (en) * 1997-09-10 1999-03-29 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
WO2000048634A1 (fr) * 1999-02-19 2000-08-24 Takeda Chemical Industries, Ltd. Preparations d'adsorption percutanee de compose ayant un antagonisme de recepteur d'angiotensine ii
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
JP4196678B2 (ja) * 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
CA2466659A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
US20050032854A1 (en) * 2001-12-03 2005-02-10 Kiminori Kawahara Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10245201A1 (de) * 2002-09-27 2004-04-15 Daimlerchrysler Ag Beschichtungszusammensetzung zur Bildung selbstschichtbildender oder selbstschichtender Lacksysteme
US7074810B2 (en) 2002-10-07 2006-07-11 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
MX2007003716A (es) * 2004-10-07 2007-04-23 Takeda Pharmaceutical Agente para la profilaxis o tratamiento del sindrome metabolico.
WO2006046593A1 (ja) 2004-10-27 2006-05-04 Daiichi Sankyo Company, Limited ２以上の置換基を有するベンゼン化合物
WO2006049304A1 (ja) * 2004-11-02 2006-05-11 Banyu Pharmaceutical Co., Ltd アリールオキシ置換ベンズイミダゾール誘導体
DE602006017183D1 (de) * 2005-03-30 2010-11-11 Takeda Pharmaceutical Benzimidazolderivat und anwendung davon
EP1871764A1 (en) * 2005-04-01 2008-01-02 LEK Pharmaceuticals D.D. A synthesis of 4-bromomethyl-2'-formylbiphenyl and 4-bromomethyl-2'- hydroxymethylbiphenyl and its use in preparation of angiotensin ii antagonists
EP1764365A1 (en) * 2005-09-20 2007-03-21 KRKA, D.D., Novo Mesto A process for the preparation of sartan derivates and intermediates useful in such process
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
US20070282099A1 (en) * 2006-06-02 2007-12-06 Steffen Zahn Heterocyclic fused imidazolone, dioxolone, imidazolethione and dioxolethione monomers
CN102813635A (zh) * 2006-08-10 2012-12-12 武田药品工业株式会社 药物组合物
ATE552818T1 (de) * 2006-09-25 2012-04-15 Takeda Pharmaceutical Medizinische verpackung
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
MX2009005449A (es) * 2006-11-24 2009-06-02 Takeda Pharmaceutical Compuesto heteromonociclico y uso del mismo.
BRPI0809522A2 (pt) * 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.
WO2008143262A1 (ja) 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GEP20135957B (en) 2008-06-19 2013-11-11 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
UY32017A (es) * 2008-07-31 2010-02-26 Takeda Pharmaceutical Composición farmacéutica sólida
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
WO2010045138A2 (en) * 2008-10-17 2010-04-22 3M Innovative Properties Company Biological sterilization indicator, system, and methods of using same
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
JP4892649B1 (ja) * 2009-01-30 2012-03-07 武田薬品工業株式会社 縮合環化合物及びその用途
PT2484675E (pt) 2009-09-29 2015-01-13 Kowa Co Novo derivado de fenilpiridina e agente medicinal que compreende o mesmo
CN102344415B (zh) * 2010-07-29 2016-04-13 上海医药工业研究院 阿奇沙坦中间体的制备方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012208863B2 (en) 2011-01-20 2016-07-28 Jiangsu Hansoh Medicine Institute Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
JP2014505097A (ja) 2011-02-08 2014-02-27 ジュビラント ライフ サイエンセズ リミテッド アジルサルタンメドキソミルの改良製造方法
CZ306650B6 (cs) * 2011-03-04 2017-04-19 Zentiva, K.S. Způsob výroby 2-ethoxy-1-((2´-((hydroxyamino)iminomethyl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylové kyseliny a jejích esterů, klíčových intermediátů syntézy azilsartanu
CN103459380B (zh) 2011-03-14 2015-07-15 兴和株式会社 苯基吡啶衍生物及含有该衍生物的医药
CZ303505B6 (cs) 2011-04-11 2012-10-24 Zentiva, K. S Zpusob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátu a jejich prevedení na azilsartan
CZ304252B6 (cs) 2011-04-11 2014-01-29 Zentiva, K. S. Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
KR101275092B1 (ko) * 2011-05-19 2013-06-17 한미정밀화학주식회사 아질사르탄의 개선된 제조방법
KR101316653B1 (ko) * 2011-05-19 2013-10-10 한미정밀화학주식회사 헤테로고리 화합물의 제조방법
WO2013030725A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Methods for treating cardiovascular disorders
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013088384A2 (en) * 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
IN2014DN06964A (hu) * 2012-02-02 2015-04-10 Ranbaxy Lab Ltd
CA2884248A1 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Novel polymorphs of azilsartan
US9624207B2 (en) 2012-08-27 2017-04-18 Hetero Research Foundation Polymorphs of azilsartan medoxomil
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
CN105237527B (zh) * 2012-09-28 2018-03-06 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
US20140113942A1 (en) * 2012-10-12 2014-04-24 Cadila Healthcare Limited Process for the preparation and purification of azilsartan medoxomil
CN103044412B (zh) * 2012-12-26 2016-04-06 华润赛科药业有限责任公司 一种阿齐沙坦的多晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN103319473A (zh) * 2013-07-02 2013-09-25 合肥医工医药有限公司 阿齐沙坦的多晶型及其制备方法
ES2847904T3 (es) 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
WO2016022626A1 (en) * 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
WO2016145622A1 (zh) * 2015-03-18 2016-09-22 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
CZ2015687A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
CN108473497B (zh) 2015-10-16 2021-09-10 卫材R&D 管理有限公司 Ep4拮抗剂
EP3434284A4 (en) 2016-03-24 2019-11-13 Daiichi Sankyo Company, Limited MEDICINE FOR THE TREATMENT OF KIDNEY DISEASE
CN112110909A (zh) * 2016-05-20 2020-12-22 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
WO2018008219A1 (ja) * 2016-07-05 2018-01-11 株式会社トクヤマ アジルサルタン中間体、アジルサルタン、及びこれらの製造方法
JP6676491B2 (ja) * 2016-07-13 2020-04-08 株式会社トクヤマ アジルサルタンアルキルエステルの製造方法、及びアジルサルタンの製造方法
JP2018076258A (ja) * 2016-11-09 2018-05-17 株式会社トクヤマ アジルサルタンアルキルエステル、アジルサルタンメチルエステルの製造方法、及びアジルサルタンの製造方法
KR101984121B1 (ko) * 2017-08-21 2019-05-30 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
CN108640911B (zh) * 2018-04-03 2020-03-27 科兴生物制药股份有限公司 一种阿齐沙坦的制备方法
KR102131022B1 (ko) * 2018-07-12 2020-07-07 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4508718A (en) * 1984-01-16 1985-04-02 Warner-Lambert Company Cardiotonic and antihypertensive oxadiazinone compounds
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5164407A (en) * 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0412594B1 (en) * 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
ATE113281T1 (de) * 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5104891A (en) * 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5011832A (en) * 1990-06-26 1991-04-30 Merck & Co., Inc. 2-biphenyl-carbapenem antibacterial agents
NZ234742A (en) * 1990-08-01 1992-10-28 Du Pont Substituted imidazole derivatives and antihypertensive compositions
NZ234744A (en) * 1990-08-01 1992-09-25 Du Pont Substituted imidazole derivatives and pharmaceutical compositions
AU636066B2 (en) * 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
FR2672892B1 (fr) * 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
EP0503838A3 (en) * 1991-03-08 1992-10-07 Merck & Co. Inc. Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
CA2062558A1 (en) * 1991-03-08 1992-09-09 Prasun K. Chakravarty Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US5210264A (en) * 1992-01-10 1993-05-11 Isis Pharmaceuticals, Inc. S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester
US5210204A (en) * 1992-06-16 1993-05-11 Warner-Lambert Company Biphenyl oxadiazoles and thiadiazoles as angiothesin II antagonists

Also Published As

Publication number Publication date
JP2645962B2 (ja) 1997-08-25
DE69233057T2 (de) 2003-12-24
JPH05271228A (ja) 1993-10-19
HU211162A9 (en) 1995-10-30
HUT71218A (en) 1995-11-28
ATE240323T1 (de) 2003-05-15
FI922977A0 (fi) 1992-06-26
JPH09183778A (ja) 1997-07-15
US5736555A (en) 1998-04-07
AU1859892A (en) 1993-01-07
PL295044A1 (en) 1993-03-08
KR930000512A (ko) 1993-01-15
US5583141A (en) 1996-12-10
JP3465215B2 (ja) 2003-11-10
US5243054A (en) 1993-09-07
SK281077B6 (sk) 2000-11-07
NO922495D0 (no) 1992-06-24
EP0520423A2 (en) 1992-12-30
PT520423E (pt) 2003-09-30
CA2072541C (en) 2005-07-05
SK199592A3 (en) 1997-01-08
AU646343B2 (en) 1994-02-17
NO922495L (no) 1992-12-28
US5883111A (en) 1999-03-16
HU218792B (hu) 2000-12-28
DE69233057D1 (de) 2003-06-18
SG65550A1 (en) 1999-06-22
IL102183A0 (en) 1993-01-14
FI922977A (fi) 1992-12-28
HU9202135D0 (en) 1992-10-28
ES2194009T3 (es) 2003-11-16
IE921861A1 (en) 1992-12-30
US6100252A (en) 2000-08-08
NZ243304A (en) 1995-01-27
EP0520423B1 (en) 2003-05-14
FI113653B (fi) 2004-05-31
DK0520423T3 (da) 2003-07-21
US5354766A (en) 1994-10-11
CA2072541A1 (en) 1992-12-28
IL102183A (en) 1999-11-30
KR100233689B1 (ko) 1999-12-01
NO300734B1 (no) 1997-07-14
EP0520423A3 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
PL173303B1 (pl) Sposób wytwarzania nowych związków heterocyklicznych
US5767283A (en) 7-Amino-1H-indoles
JP2853611B2 (ja) ベンズイミダゾール誘導体
HU211630A9 (en) Thiazolylbenzofuran derivatives and pharmaceutical composition comprising the same
EP0399732A1 (en) Benzimidazole derivatives
US5565469A (en) Benzimidazoles and pharmaceutical compositions containing them
JPH0717637B2 (ja) 置換チオフェン又はフランを組みこんだアンギオテンシンｉｉ拮抗薬
IE67956B1 (en) Benzimidazole derivatives their production and use
JPH0725739B2 (ja) ベンズイミダゾール類、これら化合物を含有する医薬およびその製法
NZ223194A (en) 1,2-dihydro-3h-indazol-3-one derivatives and 5-lipoxygenase-inhibiting compositions
US5250554A (en) Benzimidazole derivatives useful as angiotensin II inhibitors
EP0588299B1 (en) 1,2,4-Oxadiazolyl- or 1,2,4-thiadiazolyl-biphenyl derivatives as angiotensin II antagonists
RU2104276C1 (ru) Гетероциклические соединения, фармацевтическая композиция, проявляющая активность антагониста ангиотензина ii и способ антагонизирования ангиотензина ii у млекопитающих
JPH06145150A (ja) イミダゾール誘導体
RU2168510C2 (ru) Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
CZ288011B6 (cs) Bifenylheterocyklické sloučeniny, farmaceutický prostředek je obsahující, jejich použití a způsob jejich výroby
PL169116B1 (pl) Sposób wytwarzania nowych pochodnych benzimidazolu
PL170324B1 (pl) Sposób wytwarzania nowych pochodnych benzimidazolu PL
IE74902B1 (en) Benzimidazole derivatives their production and use

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20100626